

Parse Biosciences inks pact with Molecular Diagnostics Korea

07 June 2022 | News

With products now available in South Korea, partnership broadens access to single cell genomics research in Asia



US-based Parse Biosciences, a leading provider of scalable single-cell sequencing solutions, has announced a partnership with Molecular Diagnostics Korea (MDxK) that will expand its presence in Asia by providing its entire line of Evercode Whole Transcriptome products as well as Cell and Nuclei Fixation kits in South Korea.

MDxK provides instruments, consumables, and various services to support molecular research. The company's specialization in areas of multi-omics, biologics, crystallography, and bio-banking has led to its status as a premier supplier of research tools with superior outcomes.

The partnership comes shortly after the announcement of Parse Biosciences' \$41.5M Series B round in February 2022, which is enabling the company to expand commercialization of its single-cell RNA-Seq products in response to growing demand.

It further provides distribution support for the expanding product portfolio, which includes applications in immune profiling, chromatin profiling, CRISPR screens, and targeted gene panels. The Parse Biosciences approach to single-cell sequencing is based on the Evercode technology, a patented technique of split-pool combinatorial barcoding that enables researchers to sequence cells at scale without the need for expensive lab equipment.